Ottawa, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The global genomics data analysis market size was estimated at USD 6.85 billion in 2024 and is expected to hit around USD 28.74 billion by 2034, poised to grow at a CAGR of 15.24% from 2025 to 2034. A study published by Nova One Advisor a sister firm of Precedence Research.
The market is growing due to rising demand for personalized medicine and advancements in sequencing technologies that generate vast volumes of genomics data. Increasing investments in bioinformatics and AI-driven analytics further accelerate market expansion.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/9254
Genomics Data Analysis Market Key Takeaways
- North America dominated the genomics data analysis market with a revenue share in 2024.
- Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
- By service/ workflow type, the variant calling & annotation segment led the market with the largest revenue share in 2024.
- By service/ workflow type, the data preprocessing & quality control segment is expected to grow at the fastest CAGR in the market during the forecast period.
- By technology/platform, the next-generation sequencing (NGS) segment held the largest market share in 2024.
- By technology/platform, the CRISPR segment is expected to grow at the fastest CAGR in the market during the forecast period.
- By application, the drug discovery & development segment held the highest market share in 2024.
- By application, the diagnostics/ clinical diagnostics/personalized medicine segment is expected to grow at the fastest CAGR in the market during the forecast period.
- By end-user, the pharmaceutical & biotechnology companies segment dominated the market with a major revenue share.
- By end-user, the hospital & diagnostic laboratories segment is expected to grow at the fastest CAGR in the market during the forecast period.
What is Genomics Data Analysis?
Genomics data analysis is the process of interpreting and extracting meaningful insights from DNA and genetic data using computational and statistical tools. The genomics data analysis market is growing due to the rising adoption of precision medicine, increasing genomic sequencing projects, and advancements in AI and bioinformatics tools. The declining cost of sequencing and expanding applications in drug discovery, disease diagnosis, and personalized treatment further drive demand. Additionally, growing government and private investments in genomic research are accelerating market expansion globally.
- For Instance, The Genomics Health Futures Mission has allocated $500.1 million to advance genomic research, aiming to enhance disease testing and diagnosis. This initiative is expected to boost innovation in genomics and significantly support market revenue growth.
Buy Now Full Report: https://www.novaoneadvisor.com/report/checkout/9254
Report Scope of Genomics Data Analysis Market
| Report Coverage | Details |
| Market Size in 2025 | USD 7.91 Billion |
| Market Size by 2034 | USD 28.74 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 16.42% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | By Service / Workflow Type, By Technology / Platform, By Application, By End User, By Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Thermo Fisher Scientific Inc., Agilent Technologies Inc., F. Hoffmann-LA Roche Ltd., QIAGEN N.V., Pacific Biosciences of California Inc., 10x Genomics, Inc., PerkinElmer Inc., Invitae Corporation,Bio-Rad Laboratories Inc., Celerion,Myriad Genetics, Inc., SoftGenetics LLC |
For more information, visit the Nova One Advisor website or email the team at sales@novaoneadvisor.com | Call us: +1 804 420 9370
What are the Major Drivers in the Genomics Data Analysis Market?
Advancements in sequencing technologies, rising demand for personalized medicine, and increasing government and private investment in genomics research. Additionally, the growing use of AI and bioinformatics tools for large-scale data interpretation and the expanding application of genomics in disease diagnosis and drug discovery are fueling market growth.
What are the Key trends in the Genomics Data Analysis Market in 2024?
- In January 2025, NVIDIA partnered with Illumina, Mayo Clinic, and Arch Institute to integrate its AI technologies into genomic research and drug discovery. This collaboration aims to advance healthcare innovation through generative and agentic AI, driving transformation across the $10 trillion global healthcare and life sciences sector.
- In November 2024, the World Health Organization (WHO) introduced guidelines for the ethical handling of human genomic data, covering its collection, access, use, and sharing. These principles aim to safeguard individual privacy, ensure fairness, and encourage responsible global collaboration in genomic research.
What is the Emerging Challenge in the Genomics Data Analysis Market?
Managing and securing the massive volumes of complex genomic data. Issues like data privacy, standardization, interoperability, and the high costs of computational infrastructure hinder efficient analysis. Additionally, the shortage of skilled bioinformaticians and regulatory uncertainties further complicate large-scale implementation and data sharing in genomics research.
- For Instance, According to the World Health Organization (WHO), while sequencing a whole genome may cost about USD 1,000, interpreting and analyzing that genomic data can be far more expensive, reaching nearly USD 1 million due to complex data processing and advanced analytical requirements.
Immediate Delivery Available, Get Full Access @ https://www.novaoneadvisor.com/report/checkout/9254
Segmental Insights
By service/ workflow type analysis
What made the Variant Calling & Annotation Segment Dominant in the Genomics Data Analysis Market in 2024?
In 2024, the variant calling and annotation segment dominates the market due to its critical role in identifying genetic mutations linked to diseases and treatment responses. The growing use of next-generation sequencing (NGS) and precision medicine initiatives has further fueled demand for accurate variant identification and interpretation, driving significant revenue growth.
The data preprocessing & quality control segment is projected to grow at the fastest CAGR due to the increasing need for accurate, high-quality genomic datasets. As sequencing technologies generate massive data volumes, ensuring data integrity and eliminating errors becomes vital for reliable downstream analysis, clinical interpretation, and precision medicine applications, driving strong market demand.
- For Instance, In April 2024, Nonacus introduced a genomic profiling test combined with advanced bioinformatics and analysis software, enhancing data accuracy and clinical insights, which reflects the growing adoption of integrated genomic solutions in the market.
By technology/platform analysis
How did Next-generation Sequencing (NGS) Dominate the Genomics Data Analysis Market in 2024?
The next-generation sequencing (NGS) segment held the largest market share in 2024 due to its high throughput, cost efficiency, and ability to generate precise genomic data. Its wide application in clinical diagnostics, personalized medicine, and large-scale research projects has made it the preferred technology for comprehensive genetic analysis and variant detection.
The CRISPR segment is expected to grow at the fastest CAGR during the forecast period due to its precision, cost-effectiveness, and efficiency in gene editing and functional genomics. Its expanding use in therapeutics development, disease modelling, and personalized medicine, along with ongoing research advancements, is driving significant adoption across both clinical and research applications.
By application analysis
Why the Drug Discovery & Development Segment Dominated the Genomics Data Analysis Market in 2024?
The drug discovery & development segment held the highest market share in 2024 due to the growing insights to identify novel drug targets, predict therapeutic responses, and optimize treatment strategies. Pharmaceutical companies increasingly rely on genomic data to accelerate clinical trials, enhance precision medicine, and reduce overall drug development costs and timelines.
The diagnostics and personalized medicine segment is expected to grow at the fastest CAGR during the forecast period due to increasing demand for early disease detection, precision therapies, and tailored treatment approaches. Advancements in genomics sequencing and bioinformatics are enabling clinicians to identify genetic variation more accurately, driving adoption in cancer diagnostics, rare disease screening, and preventive healthcare.
By end-user analysis
Why do the Pharmaceutical & Biotechnology Companies Segment dominate the Genomics Data Analysis Market in 2024?
The pharmaceutical & biotechnology company segment dominated the market with the major revenue share due to their extensive use of genomics data in drug discovery, biomarker identification, and clinical trial optimization. These companies invest heavily in genomic technologies to accelerate R&D, improve their position in precision medicine, and advance healthcare innovation.
The hospital & diagnostic laboratory segment is expected to grow at the fastest CAGR during the forecast period due to rising adoption of genomics testing for disease diagnosis, treatment planning, and patient monitoring. Increasing integration of economic data into clinical workflows and expanding access to advanced sequencing technologies are enhancing precision care and driving demand across healthcare facilities.
By Regional Analysis
How is North America contributing to the Expansion of the Genomics Data Analysis Market?
North America dominated the market in 2024 due to strong research infrastructure, high investments in precision medicine, and the presence of major genomic technology companies. The region’s advanced healthcare systems, government-backed genomics initiatives, and widespread adoption of next-generation sequencing technologies further strengthened its leadership position, driving innovation and large-scale implementation across clinical and research applications.
How is Asia-Pacific Accelerating the Genomics Data Analysis Market?
Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to increasing investments in genomic research, expanding healthcare infrastructure, and rising awareness of personalized medicine. Countries like China, Japan, and India are advancing genomic sequencing capabilities and bioinformatics adoption, supported by government initiatives and collaborations, driving regional growth and accelerating integration of genomics into clinical and research applications.
- For Instance, In March 2025, Illumina Inc. and Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center, completed sequencing 250,000 whole genomes under the Alliance for Genomic Discovery initiative. The data is being utilized to enhance drug target identification, advance therapeutic research, and accelerate clinical development efforts in precision medicine.
Top Companies in the Genomics Data Analysis Market
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- F. Hoffmann-LA Roche Ltd.
- QIAGEN N.V.
- Pacific Biosciences of California Inc.
- 10x Genomics, Inc.
- PerkinElmer Inc.
- Invitae Corporation
- Bio-Rad Laboratories Inc.
- Celerion
- Myriad Genetics, Inc.
- SoftGenetics LLC
Download Sample @ https://www.novaoneadvisor.com/report/sample/9254
Recent Developments in the Genomics Data Analysis Market
- In February 2025, Ultima Genomics, Inc. introduced the UG 100 Solaris at the AGBT Conference, featuring upgraded chemistry, software, and streamlined workflows. These enhancements boosted sequencing output by 50% while cutting costs by 20%, making genomic analysis more efficient and affordable.
- In January 2025, NVIDIA formed new partnerships aimed at revolutionizing the $10 trillion healthcare and life sciences sector by integrating AI, accelerated computing, and biological data. These collaborations focus on advancing genomic research, speeding up drug discovery, and introducing innovative AI-driven healthcare solutions.
You can place an order or ask any questions, please feel free to contact at sales@novaoneadvisor.com | +1 804 441 9344
Related Report of Nova One Advisor:
- The global pharmacogenomics market was valued at USD 18.35 billion in 2024 and is projected to hit around USD 44.2 billion by 2034, growing at a CAGR of 9.19% during the forecast period 2025 to 2034.
- The global AI in genomics market size was estimated at USD 0.57 billion in 2023 and is expected to surpass around USD 16.84 billion by 2033 and poised to grow at a compound annual growth rate (CAGR) of 40.3% during the forecast period 2024 to 2033.
- The global forensic genomics market size was exhibited at USD 413.38 million in 2023 and is projected to hit around USD 1,571.92 million by 2033, growing at a CAGR of 14.29% during the forecast period 2024 to 2033.
- The U.S. metagenomics market size was exhibited at USD 776.85 million in 2023 and is projected to hit around USD 2,637.07 million by 2033, growing at a CAGR of 13.0% during the forecast period 2024 to 2033.
- The U.S. spatial genomics & transcriptomics market size was exhibited at USD 97.55 million in 2023 and is projected to hit around USD 328.22 million by 2033, growing at a CAGR of 12.9% during the forecast period 2024 to 2033.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the genomics data analysis market.
By Service / Workflow Type
- Variant calling & annotation
- Gene expression analysis
- Data preprocessing & quality control
- Secondary data analysis
- Tertiary/interpretation / visualization
By Technology / Platform
- Next Generation Sequencing (NGS)
- Whole Genome Sequencing (WGS)
- RNA Sequencing
- PCR & qPCR
- Microarray
- CRISPR based tools- Fastest
By Application
- Drug discovery & development
- Diagnostics / clinical diagnostics / personalized medicine
- Biomarker discovery
- Functional genomics / epigenomics / pathway analysis
By End User
- Pharmaceutical & biotechnology companies
- Hospitals & diagnostic laboratories
- Research & academic institutes
By Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Immediate Delivery Available | Buy This Premium Research
https://www.novaoneadvisor.com/report/checkout/9254
About-Us
Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.
Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.
Web: https://www.novaoneadvisor.com/
Contact Us
USA: +1 804 420 9370
Email: sales@novaoneadvisor.com
For Latest Update Follow Us: LinkedIn
Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Market Stats Insight | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
